Answers are grounded in this paper and cite their sources.
BACKGROUND Current antiviral treatment for chronic hepatitis B can suppress viral replication and reduce the risk of cirrhosis and liver cancer. It requires lifelong daily medication, and long-term adherence is often cited as a concern when initiating treatment. Hepatitis B treatment adherence in the context of the patient’s medical and life experiences remains underexplored. AIM To evaluate factors associated with adherence to hepatitis B oral antiviral treatment. METHODS A global online survey was administered anonymously to adults (aged 18 years or older) living with chronic hepatitis B. A subsample of 614 individuals who reported being on hepatitis B treatment was included in the analysis. Indices for treatment affordability, healthcare service acceptability, and individual physical, psychological, and emotional functioning were constructed (Cronbach’s alpha = 0.71-0.83). Data analysis was conducted using Stata/BE 17.0. RESULTS Overall, 81% of respondents reported high adherence to hepatitis B treatment. Lower adherence was observed among individuals who identified as African or African American (P = 0.008). Among participants with low adherence, 60% cited affordability as a challenge (P = 0.068), 53% identified healthcare service acceptability as a challenge (P = 0.04), 79% described physical functioning as a challenge (P = 0.002), and 40.5% reported difficulties with psychological functioning (P = 0.55). CONCLUSION Findings demonstrate high treatment adherence, although access to and acceptability of healthcare services, as well as an individual’s physical functioning challenges, appear to be related to low adherence.
No takes yet. Share an insight, caveat, or question.
Block et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: